{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:29:30Z","timestamp":1785810570696,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"DOI":"10.7759\/cureus.88667","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:27:48Z","timestamp":1753363668000},"source":"Crossref","is-referenced-by-count":3,"title":["Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched Analysis"],"prefix":"10.7759","author":[{"given":"Nikunj","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheen","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Mutua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Kakumanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Jai","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhay","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Walker E V, Liu JL, Davis FG, Climans S, Yuan Y. Brain Tumour Registry of Canada (BTRC). Survival and Prevalence Report 2010-2017. Brain Tumour Registry of Canada (BTRC). A Surveillance Research Collaborative. (2022). https:\/\/crdcn.ca\/publication\/brain-tumour-registry-of-canada-btrc-survival-and-prevalence-report-2010-2017\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan H","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, et al.. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009, 360:765-73. 10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat DJ","year":"2015","unstructured":"Brat DJ, Verhaak RG, Aldape KD, et al.. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015, 372:2481-98. 10.1056\/NEJMoa1402121","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1409-0","article-title":"Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups","volume":"129","author":"Weller M","year":"2015","unstructured":"Weller M, Weber RG, Willscher E, et al.. Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015, 129:679-93. 10.1007\/s00401-015-1409-0","journal-title":"Acta Neuropathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow JE","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, et al.. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015, 372:2499-508. 10.1056\/NEJMoa1407279","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\"","volume":"136","author":"Brat DJ","year":"2018","unstructured":"Brat DJ, Aldape K, Colman H, et al.. cIMPACT-NOW update 3: recommended diagnostic criteria for \"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\". Acta Neuropathol. 2018, 136:805-10. 10.1007\/s00401-018-1913-0","journal-title":"Acta Neuropathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz200","article-title":"Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria","volume":"22","author":"Tesileanu CM","year":"2020","unstructured":"Tesileanu CM, Dirven L, Wijnenga MM, et al.. Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020, 22:515-23. 10.1093\/neuonc\/noz200","journal-title":"Neuro Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000814","article-title":"Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes","volume":"83","author":"Labussi\u00e8re M","year":"2014","unstructured":"Labussi\u00e8re M, Boisselier B, Mokhtari K, et al.. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014, 83:1200-6. 10.1212\/WNL.0000000000000814","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1163-0","article-title":"TERT promoter mutations in primary and secondary glioblastomas","volume":"126","author":"Nonoguchi N","year":"2013","unstructured":"Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013, 126:931-7. 10.1007\/s00401-013-1163-0","journal-title":"Acta Neuropathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1207-5","article-title":"Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors","volume":"126","author":"Reitman ZJ","year":"2013","unstructured":"Reitman ZJ, Pirozzi CJ, Yan H. Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathol. 2013, 126:789-92. 10.1007\/s00401-013-1207-5","journal-title":"Acta Neuropathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela PJ","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, et al.. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013, 110:6021-6. 10.1073\/pnas.1303607110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-013-0148-y","article-title":"Subgrouping of gliomas on the basis of genetic profiles","volume":"30","author":"Hirose Y","year":"2013","unstructured":"Hirose Y, Sasaki H, Abe M, et al.. Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathol. 2013, 30:203-8. 10.1007\/s10014-013-0148-y","journal-title":"Brain Tumor Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1454-8","article-title":"Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities","volume":"130","author":"Reuss DE","year":"2015","unstructured":"Reuss DE, Kratz A, Sahm F, et al.. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015, 130:407-17. 10.1007\/s00401-015-1454-8","journal-title":"Acta Neuropathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1905-0","article-title":"Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma","volume":"136","author":"Stichel D","year":"2018","unstructured":"Stichel D, Ebrahimi A, Reuss D, et al.. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018, 136:793-803. 10.1007\/s00401-018-1905-0","journal-title":"Acta Neuropathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \"target delineation of glioblastomas\"","volume":"118","author":"Niyazi M","year":"2016","unstructured":"Niyazi M, Brada M, Chalmers AJ, et al.. ESTRO-ACROP guideline \"target delineation of glioblastomas\". Radiother Oncol. 2016, 118:35-42. 10.1016\/j.radonc.2015.12.003","journal-title":"Radiother Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04737-9","article-title":"Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance","volume":"169","author":"Lee M","year":"2024","unstructured":"Lee M, Karschnia P, Park YW, et al.. Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance. J Neurooncol. 2024, 169:531-41. 10.1007\/s11060-024-04737-9","journal-title":"J Neurooncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-038","article-title":"Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma","volume":"10","author":"Filippini G","year":"2008","unstructured":"Filippini G, Falcone C, Boiardi A, et al.. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008, 10:79-87. 10.1215\/15228517-2007-038","journal-title":"Neuro Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.9.704","article-title":"Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials","volume":"85","author":"Curran WJ Jr","year":"1993","unstructured":"Curran WJ Jr, Scott CB, Horton J, et al.. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993, 85:704-10. 10.1093\/jnci\/85.9.704","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis","volume":"6","author":"Lamborn KR","year":"2004","unstructured":"Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004, 6:227-35. 10.1215\/S1152851703000620","journal-title":"Neuro Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.9.5612","article-title":"Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene","volume":"17","author":"Watts GS","year":"1997","unstructured":"Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997, 17:5612-9. 10.1128\/MCB.17.9.5612","journal-title":"Mol Cell Biol"},{"key":"ref24","article-title":"Methylation hot spots in the 5\u2019 flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene","volume":"57","author":"Qian XC","year":"1997","unstructured":"Qian XC, Brent TP. Methylation hot spots in the 5\u2019 flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1997, 57:3672-7.","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The","volume":"10","author":"Stupp R","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The. Lancet Oncology. 2009, 10:459-66. 10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03960-6","article-title":"The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study","volume":"157","author":"Ramos-Fresnedo A","year":"2022","unstructured":"Ramos-Fresnedo A, Pullen MW, Perez-Vega C, et al.. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. 2022, 157:177-85. 10.1007\/s11060-022-03960-6","journal-title":"J Neurooncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21221","article-title":"The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years","volume":"104","author":"Korshunov A","year":"2005","unstructured":"Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age &lt;50 years. Cancer. 2005, 104:825-32. 10.1002\/cncr.21221","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12481","article-title":"Prognostic factors for glioblastoma patients - a clinical population-based study","volume":"133","author":"Fekete B","year":"2016","unstructured":"Fekete B, Werlenius K, \u00d6rndal C, Rydenhag B. Prognostic factors for glioblastoma patients - a clinical population-based study. Acta Neurol Scand. 2016, 133:434-41. 10.1111\/ane.12481","journal-title":"Acta Neurol Scand"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9538-0","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients","volume":"88","author":"Minniti G","year":"2008","unstructured":"Minniti G, De Sanctis V, Muni R, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008, 88:97-103. 10.1007\/s11060-008-9538-0","journal-title":"J Neurooncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-023-00463-8","article-title":"IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis","volume":"40","author":"Nakasu S","year":"2023","unstructured":"Nakasu S, Deguchi S, Nakasu Y. IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis. Brain Tumor Pathol. 2023, 40:143-57. 10.1007\/s10014-023-00463-8","journal-title":"Brain Tumor Pathol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad075","article-title":"Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation","volume":"5","author":"Wijnenga MM","year":"2023","unstructured":"Wijnenga MM, Maas SL, van Dis V, et al.. Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation. Neurooncol Adv. 2023, 5:vdad075. 10.1093\/noajnl\/vdad075","journal-title":"Neurooncol Adv"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa258","article-title":"IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification","volume":"23","author":"Berzero G","year":"2021","unstructured":"Berzero G, Di Stefano AL, Ronchi S, et al.. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 2021, 23:955-66. 10.1093\/neuonc\/noaa258","journal-title":"Neuro Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa W","year":"2004","unstructured":"Roa W, Brasher PM, Bauman G, et al.. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004, 22:1583-8. 10.1200\/JCO.2004.06.082","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry JR","year":"2017","unstructured":"Perry JR, Laperriere N, O'Callaghan CJ, et al.. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017, 376:1027-37. 10.1056\/NEJMoa1611977","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0777-8","article-title":"Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis","volume":"120","author":"Metellus P","year":"2010","unstructured":"Metellus P, Coulibaly B, Colin C, et al.. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010, 120:719-29. 10.1007\/s00401-010-0777-8","journal-title":"Acta Neuropathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03995-9","article-title":"Gyriform infiltration as imaging biomarker for molecular glioblastomas","volume":"157","author":"Mesny E","year":"2022","unstructured":"Mesny E, Barritault M, Izquierdo C, et al.. Gyriform infiltration as imaging biomarker for molecular glioblastomas. J Neurooncol. 2022, 157:511-21. 10.1007\/s11060-022-03995-9","journal-title":"J Neurooncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy513","article-title":"Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations","volume":"85","author":"Izquierdo C","year":"2019","unstructured":"Izquierdo C, Barritault M, Poncet D, et al.. Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery. 2019, 85:E448-56. 10.1093\/neuros\/nyy513","journal-title":"Neurosurgery"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1797-y","article-title":"MRI findings and pathological features in early-stage glioblastoma","volume":"123","author":"Ideguchi M","year":"2015","unstructured":"Ideguchi M, Kajiwara K, Goto H, Sugimoto K, Nomura S, Ikeda E, Suzuki M. MRI findings and pathological features in early-stage glioblastoma. J Neurooncol. 2015, 123:289-97. 10.1007\/s11060-015-1797-y","journal-title":"J Neurooncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1148\/radiographics.16.6.8946545","article-title":"Glioblastoma multiforme: radiologic-pathologic correlation","volume":"16","author":"Rees JH","year":"1996","unstructured":"Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. 1996, 16:1413-38. 10.1148\/radiographics.16.6.8946545","journal-title":"Radiographics"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac197","article-title":"IDH1\/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1\/2 wildtype glioblastomas","volume":"25","author":"van Opijnen MP","year":"2023","unstructured":"van Opijnen MP, Tesileanu CM, Dirven L, et al.. IDH1\/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1\/2 wildtype glioblastomas. Neuro Oncol. 2023, 25:701-9. 10.1093\/neuonc\/noac197","journal-title":"Neuro Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti F","year":"2002","unstructured":"Pignatti F, van den Bent M, Curran D, et al.. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002, 20:2076-84. 10.1200\/JCO.2002.08.121","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383468-survival-impact-of-isocitrate-dehydrogenase-idh-wildtype-histological-versus-molecular-glioblastoma-a-propensity-score-matched-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:27:50Z","timestamp":1753363670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383468-survival-impact-of-isocitrate-dehydrogenase-idh-wildtype-histological-versus-molecular-glioblastoma-a-propensity-score-matched-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.88667","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}